TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Up 37.0% in March

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 11,100 shares, an increase of 37.0% from the March 15th total of 8,100 shares. Based on an average daily volume of 9,300 shares, the short-interest ratio is presently 1.2 days.

TriSalus Life Sciences Price Performance

TLSIW opened at $0.99 on Monday. The stock has a fifty day moving average of $1.03 and a 200-day moving average of $0.73. TriSalus Life Sciences has a fifty-two week low of $0.02 and a fifty-two week high of $1.35.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds have recently bought and sold shares of the business. Clear Street LLC bought a new position in TriSalus Life Sciences during the 4th quarter worth $60,000. Context Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth $27,000. Shaolin Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth $29,000. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences in the fourth quarter worth $123,000. Finally, Walleye Capital LLC acquired a new position in TriSalus Life Sciences in the third quarter valued at about $40,000.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.